查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827443

甲狀腺癌藥物市場按癌症類型、治療方式、藥物類型、給藥方法和最終用戶分類－2025-2032 年全球預測

Thyroid Cancer Drugs Market by Cancer Type, Treatment Modality, Drug Type, Mode Of Administration, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年甲狀腺癌藥物市場規模將成長至 21.1444 億美元，複合年成長率為 11.40%。

主要市場統計數據
基準年2024年 8.9096億美元
預計2025年 9.9483億美元
預測年份：2032年 2,114,440,000美元
複合年成長率（%） 11.40%

為策略決策者提供關於重塑甲狀腺癌治療格局的臨床、商業和營運促進因素的全面概述

甲狀腺癌治療領域正在經歷快速的科學和臨床變革，新的治療方法正在重塑臨床路徑和相關人員的期望。本執行摘要旨在幫助讀者了解甲狀腺癌治療領域的最新進展，涵蓋治療方法、產品類別和最終用戶動態，並概述其對製造商、付款方、醫療保健提供者和臨床研究人員的戰略意義。

本書以疾病異質性和臨床緊迫性的簡明框架為開端，闡述了當代治療組合及其推動變革的力量，包括監管核准、真實世界證據的生成以及醫療服務模式的轉變。本書重點介紹了分子標靶療法、免疫腫瘤藥物、手術和放射性碘等成熟治療方法之間的相互作用，並強調了多學科治療決策如何依賴日益複雜的生物標記和基因組資訊。

重要的是，引言還強調了伴隨科學進步的商業性和營運考慮，從供應鏈彈性到患者獲取途徑，從而為甲狀腺癌治療的策略規劃和投資優先奠定基礎。

精準診斷、監管靈活性和門診護理的趨勢如何融合，從而改變甲狀腺癌的治療模式和相關人員的角色

過去幾年，甲狀腺癌的治療模式已從相對靜態的治療模式轉變為以動態創新和治療多樣化為特徵的模式。精準診斷和分子分層強調了標靶治療的重要性，使臨床醫生能夠根據腫瘤的突變特徵和抗藥性模式製定治療方法。因此，多激酶抑制劑和選擇性標靶藥物的臨床作用不斷擴大，同時，針對具有挑戰性的組織學亞型的免疫療法聯合治療也日益受到探索。

隨著科學的進步，法律規範也隨之調整，以適應加速核准、有條件核准以及生物標記定義人群驅動的擴大上市許可。衛生系統正在透過投資多學科腫瘤委員會和基因組檢測基礎設施來應對這些變化，從而影響轉診模式和治療順序。此外，口服腫瘤藥物和門診病人治療方案的成熟正在影響劑量、依從性和長期患者管理，使治療不再局限於住院。

簡而言之，精準醫療、監管靈活性和醫療保健服務重組的整合正在推動變革性轉變，為創新療法創造機遇，也為製造商和醫療保健提供者帶來商業挑戰。

評估2025年關稅主導的供應鏈重組及其對甲狀腺癌藥物採購、臨床營運和取得策略的下游影響

2025年關稅的實施和貿易政策的調整為全球醫藥供應鏈帶來了新的變量，並對營運和策略產生了顯著的影響。對於通常依賴複雜原料藥採購和跨境生產的甲狀腺癌治療藥物而言，進口關稅的提高凸顯了供應鏈規劃和雙重籌資策略的重要性。這些累積效應促使人們重新關注如何重新評估採購慣例並最佳化生產佈局，以減輕關稅波動的影響。

此外，關稅也強化了提高成本和定價策略透明度的必要性。企業擴大將潛在的貿易相關成本壓力納入採購合約和長期供應商夥伴關係中。臨床試驗物流也受到影響，臨床試驗贊助者在調整其場地選擇和臨床實驗藥物分銷計劃，以減少與海關相關的延誤，並確保患者能夠持續獲得臨床實驗藥物。

最後，這些不利因素正促使相關人員加快對近岸製造、供應彈性計畫和合作協定模式的投資。這些調整旨在確保治療的可獲得性，保障患者獲得藥物，同時在不斷變化的關稅環境下保持可預測的交貨時間表。

詳細的細分分析將癌症組織學、治療方式、藥物類別、給藥途徑和最終用戶動態與商業化和臨床策略要務聯繫起來

基於細分的洞察揭示了細微的模式，可為產品開發、上市規劃和臨床定位提供參考。我們基於癌症類型的分析涵蓋甲狀腺未分化癌 (ATC)、濾泡性甲狀腺癌 (FTC)、許爾特爾細胞癌、甲狀腺髓樣癌 (MTC) 和甲狀腺乳頭狀癌 (PTC)，重點關注它們獨特的自然病程和治療需求，從而驅動不同的臨床重點和循證策略。我們根據治療方式，研究了化療、免疫療法、放射性碘治療、手術、標靶多激酶療法和甲狀腺刺激素(TSH) 抑制療法，並展示了特定治療方式的價值提案如何影響藥物的採用、報銷途徑和跨專業協作。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 高選擇性RET激酶抑制劑的出現改善了特異性患者的治療
  • 整合液態生物檢體基因組分析用於甲狀腺癌的早期檢測和治療監測
  • 第二代多激酶抑制劑治療放射性碘難治性甲狀腺癌的核准和市場滲透
  • 開發結合 BRAF 抑制劑和免疫療法的聯合治療以克服甲狀腺癌的抗藥性
  • 擴大患者可及性計畫將促進新興市場採用昂貴的甲狀腺癌標靶治療
  • 針對新型抗原的CAR-T細胞療法在治療未分化甲狀腺癌的進展
  • 胜肽受體放射性核種治療進行性甲狀腺髓樣癌的監管核准
  • 採用真實世界證據研究證明新型甲狀腺癌治療方法的有效性與安全性

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章 甲狀腺癌治療藥物市場（依癌症類型）

  • 未分化甲狀腺癌（ATC）
  • 濾泡性甲狀腺癌（FTC）
  • 赫特爾細胞癌
  • 甲狀腺髓樣癌（MTC）
  • 甲狀腺乳突癌（PTC）

9. 甲狀腺癌藥物市場（依治療方法）

  • 化療
  • 免疫療法
  • 放射性碘治療
  • 外科手術
  • 標靶多激酶治療
  • 甲狀腺刺激素（TSH）抑制治療

第 10 章 甲狀腺癌藥物市場（依藥物類型）

  • 化療藥物
  • 荷爾蒙療法藥物
  • 免疫療法
  • 標靶治療藥物

第11章 甲狀腺癌藥物市場依給藥方式

  • 注射
    • 預填充式注射器
    • 管瓶
  • 口服
    • 膠囊
    • 藥片

第 12 章 甲狀腺癌藥物市場（依最終使用者）

  • 居家照護環境
  • 醫院
  • 腫瘤診所
  • 研究機構

第13章 甲狀腺癌藥物市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 甲狀腺癌藥物市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 甲狀腺癌藥物市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Eisai Co., Ltd.
    • Exelixis, Inc.
    • Bayer AG
    • AstraZeneca PLC
    • Blueprint Medicines Corporation
    • Eli Lilly and Company
    • Merck & Co., Inc.
    • Merck KGaA
    • Novartis AG
    • Pfizer Inc.
Product Code: MRR-434CCDA052BE

The Thyroid Cancer Drugs Market is projected to grow by USD 2,114.44 million at a CAGR of 11.40% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 890.96 million
Estimated Year [2025] USD 994.83 million
Forecast Year [2032] USD 2,114.44 million
CAGR (%) 11.40%

Comprehensive overview of clinical, commercial, and operational drivers reshaping the thyroid cancer treatment landscape for strategic decision-makers

The therapeutic landscape for thyroid cancer is undergoing rapid scientific and clinical evolution, with novel modalities reshaping clinical pathways and stakeholder expectations. This executive summary sets out to orient readers to the current state of play across treatment approaches, product classes, and end-user dynamics, and to outline strategic implications for manufacturers, payers, providers, and clinical researchers.

Beginning with a concise framing of disease heterogeneity and clinical urgency, the narrative moves through the contemporary therapeutic mix and the forces driving change, including regulatory approvals, real-world evidence generation, and shifts in care delivery. Emphasis is given to the interplay between targeted molecular therapies, immuno-oncology agents, and established modalities such as surgery and radioiodine, underscoring how multidisciplinary treatment decisions now rely on increasingly precise biomarker and genomic information.

Importantly, the introduction also highlights commercial and operational considerations that accompany scientific progress - from supply chain resilience to patient access pathways - setting the context for the deeper analytical sections that follow. This establishes the foundation for informed strategic planning and investment prioritization in thyroid cancer therapeutics.

How precision diagnostics, regulatory flexibility, and outpatient care trends are converging to transform thyroid cancer treatment paradigms and stakeholder roles

Across the past several years, the thyroid cancer landscape has shifted from a relatively static treatment paradigm to one characterized by dynamic innovation and therapeutic diversification. Precision diagnostics and molecular stratification have elevated the importance of targeted therapies, enabling clinicians to tailor treatment regimens to tumor mutation profiles and resistance patterns. Consequently, the clinical role of multikinase inhibitors and selective targeted agents has expanded, while immunotherapy combinations are increasingly explored for difficult-to-treat histologies.

Parallel to scientific advances, regulatory frameworks have adapted to accommodate accelerated approval pathways, conditional authorizations, and label expansions driven by biomarker-defined cohorts. Health systems are responding to these changes by investing in multidisciplinary tumor boards and genomic testing infrastructure, which in turn influence referral patterns and treatment sequencing. Additionally, the maturation of oral onco-pharmaceuticals and outpatient-centered regimens is shifting care away from inpatient settings, with implications for administration, adherence, and long-term patient management.

In short, transformative shifts are being driven by a convergence of precision medicine, regulatory flexibility, and care-delivery realignment, creating both opportunities for innovative therapeutics and operational challenges for manufacturers and providers alike.

Assessment of 2025 tariff-driven supply chain recalibrations and their downstream effects on procurement, clinical operations, and access strategies for thyroid cancer therapies

The imposition of tariffs and trade policy adjustments in 2025 introduced new variables into the global pharmaceutical supply chain with measurable operational and strategic consequences. For thyroid cancer therapeutics, which often rely on complex active pharmaceutical ingredient sourcing and cross-border manufacturing, increased import duties have amplified the importance of supply chain mapping and dual-sourcing strategies. The cumulative effect has been a re-evaluation of procurement practices and a renewed focus on manufacturing footprint optimization to mitigate exposure to tariff volatility.

Moreover, tariffs have reinforced the need for greater transparency in costing and pricing strategy. Organizations are increasingly factoring potential trade-related cost pressures into procurement contracts and long-term supplier partnerships. Clinical trial logistics have also been impacted, with sponsors adjusting trial site selection and investigational medicinal product distribution plans to reduce customs-related delays and ensure continuity of patient access to investigational therapies.

Finally, in response to these headwinds, stakeholders have accelerated investments in near-shore manufacturing, supply resiliency programs, and collaborative contracting models. These adaptations aim to preserve therapeutic availability and protect patient access while maintaining predictable delivery timelines in a changing tariff environment.

Deep segmentation analysis linking cancer histology, treatment modality, drug class, administration route, and end-user dynamics to commercialization and clinical strategy imperatives

Segmentation-based insights reveal nuanced patterns that inform product development, market access planning, and clinical positioning. Based on Cancer Type, the analysis covers Anaplastic Thyroid Cancer (ATC), Follicular Thyroid Cancer (FTC), Hurthle Cell Carcinoma, Medullary Thyroid Cancer (MTC), and Papillary Thyroid Cancer (PTC), highlighting the distinct natural histories and therapeutic needs that dictate differential clinical priorities and evidence generation strategies. Based on Treatment Modality, the study examines Chemotherapy, Immunotherapy, Radioiodine Therapy, Surgery, Targeted Multikinase Therapy, and Thyroid Stimulating Hormone (TSH) Suppression Therapy, demonstrating how modality-specific value propositions influence adoption, reimbursement pathways, and cross-specialty coordination.

Based on Drug Type, distinctions among Chemotherapy Agents, Hormone Therapy Drugs, Immunotherapy Drugs, and Targeted Therapy Drugs underscore the varying development timelines, safety profiles, and companion diagnostic dependencies that sponsors must navigate. Based on Mode Of Administration, injectable and oral forms are evaluated, with the Injectable further disaggregated into Pre-Filled Syringes and Vials and the Oral subdivided into Capsules and Tablets; this distinction influences manufacturing complexity, patient adherence patterns, and distribution logistics. Based on End User, the report addresses Homecare Settings, Hospitals, Oncology Clinics, and Research Organizations, each representing unique purchasing behaviors, clinical workflows, and post-market evidence opportunities.

Taken together, these segmentation lenses demonstrate that effective commercialization strategies require an integrated approach that aligns clinical development with administration logistics and end-user dynamics, while also prioritizing evidence generation that resonates with the decision criteria of diverse stakeholder groups.

Region-specific clinical, regulatory, and access dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine adoption and market entry strategies

Regional intelligence highlights distinct regulatory, clinical, and access dynamics that shape therapeutic strategy across global markets. In the Americas, the regulatory environment emphasizes expedited review pathways and robust real-world evidence collection, which supports accelerated uptake for biomarker-driven therapies and creates opportunities for outcome-based contracting and managed entry agreements. Clinical practice in this region tends to integrate multidisciplinary care delivery models and advanced genomic testing, driving early adoption of precision therapeutics and oral treatment regimens.

In Europe, Middle East & Africa, fragmentation across regulatory frameworks and reimbursement systems necessitates tailored market entry tactics that account for country-level HTA processes, variability in diagnostic infrastructure, and differences in hospital procurement. Stakeholders should prioritize evidence packages that align with regional HTA endpoints and invest in local clinician engagement to navigate heterogeneous payer environments. Additionally, capacity constraints in parts of the region can influence access to advanced modalities such as radioiodine therapy and immuno-oncology combinations.

In Asia-Pacific, diverse regulatory timelines and accelerating investment in oncology research create a complex but opportunity-rich landscape. Many jurisdictions in this region are expanding molecular testing and decentralizing cancer care, which in turn supports broader population access to targeted and oral therapies. Strategic partnerships with local manufacturers, attention to pricing and reimbursement nuances, and investment in regional real-world evidence generation will be critical to achieving sustainable access and uptake across Asia-Pacific markets.

Competitive and corporate strategies that define success in thyroid oncology including pipeline prioritization, diagnostics partnerships, and outcome-driven commercialization capabilities

Company-level dynamics are central to competitive positioning and therapeutic differentiation in thyroid oncology. Leading pharmaceutical and biotechnology companies are advancing pipelines through a combination of internal discovery, strategic collaborations, and targeted acquisitions, with particular emphasis on agents that address unmet needs in aggressive or refractory histologies. Across the competitive set, successful companies are those that couple robust clinical programs with clear companion diagnostic strategies and post-authorization evidence generation plans.

Commercially, organizations that invest in integrated launch capabilities - combining payer engagement, clinician education, and patient support services - are better positioned to accelerate uptake of new therapies. Operational excellence in supply chain management and manufacturing scale-up is equally critical to avoid launch disruptions and to support global demand. Partnerships between biopharma firms and diagnostic providers are increasingly common, reflecting the need to bundle testing and treatment pathways to optimize clinical outcomes and payer value assessments.

Finally, companies demonstrating agility in pricing models and contracting arrangements, including risk-sharing agreements and value-based frameworks, are more likely to secure access in environments where payers demand demonstrable outcomes. These company-level approaches collectively define who will convert clinical innovation into sustained therapeutic impact.

Practical and high-impact recommendations for manufacturers and payers to align diagnostics, supply resilience, patient support, and flexible contracting for sustained therapeutic success

Industry leaders should adopt a set of targeted actions to translate scientific progress into sustainable patient impact. Prioritize integration of molecular diagnostics into clinical development plans early, aligning study endpoints with payer-relevant outcomes to streamline reimbursement discussions. Simultaneously, invest in supply chain redundancies and near-shore manufacturing options to mitigate tariff and trade-related disruptions while preserving timely access to critical therapies.

Moreover, foster collaborations across the ecosystem by forming partnerships with diagnostic companies, academic centers, and regional distributors to expedite adoption and to build localized evidence. Enhance patient support programs to address adherence and administration barriers, particularly as oral regimens and homecare delivery models become more prevalent. From a commercial perspective, develop flexible contracting strategies that allow for outcome-based elements and adaptive pricing aligned with real-world performance.

Finally, embed agile decision-making processes into R&D and commercial operations so that learnings from early real-world deployments can rapidly inform label expansions, combination therapy studies, and lifecycle management. These actions will help organizations convert innovation into measurable clinical and commercial success.

Robust mixed-methods research framework combining expert interviews, secondary evidence review, and validation techniques to ensure actionable and credible insights

The research approach underpinning this analysis combines structured primary research with comprehensive secondary synthesis and rigorous validation. Primary inputs were derived from in-depth interviews with clinical experts, senior clinicians across relevant specialties, supply chain leaders, and payers to capture first-hand perspectives on treatment patterns, access hurdles, and operational realities. Secondary synthesis incorporated peer-reviewed literature, regulatory documentation, clinical trial registries, and publicly available product labels to contextualize therapeutic mechanisms and evidence maturations.

Data validation involved triangulating stakeholder interviews with clinical guideline trends and regulatory actions to ensure consistency and to identify divergences between trial settings and real-world practice. The methodology also employed scenario analysis to stress-test assumptions around supply disruptions, policy shifts, and treatment pathway changes. Where applicable, patient pathway mapping was used to surface friction points in diagnosis, treatment initiation, and long-term follow-up.

Collectively, these methodological elements ensure that the insights presented are grounded in real-world clinical practice and operational feasibility, providing a robust foundation for strategic decision-making by industry and clinical stakeholders.

Strategic synthesis of clinical, commercial, and operational imperatives that stakeholders must address to convert innovation into improved patient outcomes

In conclusion, the thyroid cancer therapeutic arena is transitioning toward a more personalized, evidence-driven paradigm in which diagnostics, therapeutics, and care delivery are tightly interdependent. Precision medicine advances and new regulatory pathways are enabling faster clinical translation, but they also demand sophisticated commercialization and operational strategies to ensure patient access and to sustain clinical benefit. Moreover, external dynamics such as tariff-induced supply chain risks and regional policy heterogeneity underscore the importance of adaptive planning and collaborative partnerships.

For stakeholders seeking to lead in this environment, success will hinge on aligning clinical development with payer-relevant evidence, building resilient manufacturing and distribution networks, and investing in end-user engagement across hospitals, clinics, and homecare settings. By doing so, manufacturers, providers, and policymakers can collectively improve outcomes for diverse thyroid cancer patient populations while navigating the complex commercial and operational landscape.

This summary provides a strategic vantage point for executives and clinicians to prioritize initiatives that will have the greatest impact on patient care and organizational performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of highly selective RET kinase inhibitors improving patient-specific therapy
  • 5.2. Integration of liquid biopsy genomic profiling in early detection and treatment monitoring for thyroid cancer
  • 5.3. Approval and market uptake of second-generation multikinase inhibitors for radioiodine refractory thyroid carcinoma
  • 5.4. Development of combination regimens pairing BRAF inhibitors with immunotherapy to overcome resistance in thyroid cancer
  • 5.5. Expansion of patient access programs driving uptake of costly targeted therapies in emerging markets for thyroid cancer treatment
  • 5.6. Advances in CAR T cell therapies targeting novel antigens in anaplastic thyroid carcinoma management
  • 5.7. Regulatory approvals of peptide receptor radionuclide therapy for advanced medullary thyroid carcinoma patients
  • 5.8. Adoption of real-world evidence studies informing efficacy and safety of new thyroid cancer treatment modalities

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Thyroid Cancer Drugs Market, by Cancer Type

  • 8.1. Anaplastic Thyroid Cancer (ATC)
  • 8.2. Follicular Thyroid Cancer (FTC)
  • 8.3. Hurthle Cell Carcinoma
  • 8.4. Medullary Thyroid Cancer (MTC)
  • 8.5. Papillary Thyroid Cancer (PTC)

9. Thyroid Cancer Drugs Market, by Treatment Modality

  • 9.1. Chemotherapy
  • 9.2. Immunotherapy
  • 9.3. Radioiodine Therapy
  • 9.4. Surgery
  • 9.5. Targeted Multikinase Therapy
  • 9.6. Thyroid Stimulating Hormone (TSH) Suppression Therapy

10. Thyroid Cancer Drugs Market, by Drug Type

  • 10.1. Chemotherapy Agents
  • 10.2. Hormone Therapy Drugs
  • 10.3. Immunotherapy Drugs
  • 10.4. Targeted Therapy Drugs

11. Thyroid Cancer Drugs Market, by Mode Of Administration

  • 11.1. Injectable
    • 11.1.1. Pre-Filled Syringes
    • 11.1.2. Vials
  • 11.2. Oral
    • 11.2.1. Capsules
    • 11.2.2. Tablets

12. Thyroid Cancer Drugs Market, by End User

  • 12.1. Homecare Settings
  • 12.2. Hospitals
  • 12.3. Oncology Clinics
  • 12.4. Research Organizations

13. Thyroid Cancer Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Thyroid Cancer Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Thyroid Cancer Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Eisai Co., Ltd.
    • 16.3.2. Exelixis, Inc.
    • 16.3.3. Bayer AG
    • 16.3.4. AstraZeneca PLC
    • 16.3.5. Blueprint Medicines Corporation
    • 16.3.6. Eli Lilly and Company
    • 16.3.7. Merck & Co., Inc.
    • 16.3.8. Merck KGaA
    • 16.3.9. Novartis AG
    • 16.3.10. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL THYROID CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. THYROID CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. THYROID CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. THYROID CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL THYROID CANCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL THYROID CANCER DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ANAPLASTIC THYROID CANCER (ATC), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ANAPLASTIC THYROID CANCER (ATC), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ANAPLASTIC THYROID CANCER (ATC), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ANAPLASTIC THYROID CANCER (ATC), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ANAPLASTIC THYROID CANCER (ATC), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ANAPLASTIC THYROID CANCER (ATC), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY FOLLICULAR THYROID CANCER (FTC), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY FOLLICULAR THYROID CANCER (FTC), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY FOLLICULAR THYROID CANCER (FTC), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY FOLLICULAR THYROID CANCER (FTC), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY FOLLICULAR THYROID CANCER (FTC), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY FOLLICULAR THYROID CANCER (FTC), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HURTHLE CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HURTHLE CELL CARCINOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HURTHLE CELL CARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HURTHLE CELL CARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HURTHLE CELL CARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HURTHLE CELL CARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MEDULLARY THYROID CANCER (MTC), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MEDULLARY THYROID CANCER (MTC), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MEDULLARY THYROID CANCER (MTC), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MEDULLARY THYROID CANCER (MTC), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MEDULLARY THYROID CANCER (MTC), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MEDULLARY THYROID CANCER (MTC), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PAPILLARY THYROID CANCER (PTC), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PAPILLARY THYROID CANCER (PTC), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PAPILLARY THYROID CANCER (PTC), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PAPILLARY THYROID CANCER (PTC), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PAPILLARY THYROID CANCER (PTC), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PAPILLARY THYROID CANCER (PTC), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RADIOIODINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RADIOIODINE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RADIOIODINE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RADIOIODINE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RADIOIODINE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RADIOIODINE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED MULTIKINASE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED MULTIKINASE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED MULTIKINASE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED MULTIKINASE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED MULTIKINASE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED MULTIKINASE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY THYROID STIMULATING HORMONE (TSH) SUPPRESSION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY THYROID STIMULATING HORMONE (TSH) SUPPRESSION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY THYROID STIMULATING HORMONE (TSH) SUPPRESSION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY THYROID STIMULATING HORMONE (TSH) SUPPRESSION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY THYROID STIMULATING HORMONE (TSH) SUPPRESSION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY THYROID STIMULATING HORMONE (TSH) SUPPRESSION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY VIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY VIALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY VIALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY VIALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY VIALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY VIALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 306. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 307. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 310. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 311. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 312. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 313. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 314. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 315. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. GCC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. GCC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. GCC THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. G